MICROGEN, LLC

Medtech · Private

One-Step diagnostic platform integrating sample lysis and target amplification for rapid CMV detection in dried blood spots

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Medtech
Total capital
$4.1M
Federal grants
$4.1M
8 awards · 2017–2025
Rank in peer group#213 of 538
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20172019202120232025FEDERAL ↑EQUITY ↓Cumulative $4.1M$223K$292K$1M$300K$999K$944K
20172019202120232025FEDERAL ↑EQUITY ↓Cumulative $4.1M$1M$999K$944K

Latest events

  • Federal grantHealth and Human S · Phase II · Development of a High Throughput Assay for Rapid Screening of Congenital Cytomegalovirus Infection using Dried Blood Spots$944K
  • Federal grantHealth and Human S · Phase II · Development of a High Throughput Assay for Rapid Screening of Congenital Cytomegalovirus Infection using Dried Blood Spots$999K
  • Federal grantHealth and Human S · Phase I · PA21259, SBIR, Phase I, Development of a High Throughput Assay for Rapid Detection of HSV and Treponema pallidum$300K
  • Federal grantHealth and Human S · Phase II · Development of a High Throughput Assay for Rapid Screening of Congenital Cytomegalovirus Infection using Dried Blood Spots$1M
  • Federal grantHealth and Human S · Phase I · Development of a High Throughput Assay for Rapid Screening of Congenital Cytomegalovirus Infection using Dried Blood Spots$292K
  • Federal grantHealth and Human S · Phase I · Rapid User Friendly POC Diagnostic for HSV$190K
  • Federal grantHealth and Human S · Phase I · Low Cost Point-Of-Care Test For CMV$122K
Show 1 earlier federal award
  • Federal grantHealth and Human S · Phase I · Low Cost Point-Of-Care Test For CMV$223K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 538 peers

Line = median

Medtech · Device

  • Federal grants#213 · top 40%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .